Research Paper Volume 14, Issue 15 pp 6358—6376
Clinical outcomes and potential therapies prediction of subgroups based on a ferroptosis-related long non-coding RNA signature for gastric cancer
Figure 8. Experimental validation and parallel comparison of FRLSG. The expression level of (A) AL049840.4, (B) AC005532.1, (C) AC004816.1, (D) LINC01357, (E) AL355574.1 in the GES1, HGC27 and AGS. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. (F) Time-dependent AUC for the comparison of FRLSG with other four previously published ferroptosis-related lncRNAs signatures for GC.